Kyverna Therapeutics, Inc. announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its autologous, fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of stiff-person syndrome (SPS) in Kyverna's trial, named KYSA-8.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.36 USD | +1.24% | -8.34% | 0.00% |
06-24 | Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to S&P Global BMI Index | CI |
06-20 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 317M | |
+21.85% | 46.44B | |
+38.65% | 39.1B | |
-8.05% | 38.76B | |
+29.04% | 31.24B | |
-13.75% | 25.8B | |
+10.65% | 25.9B | |
+38.43% | 13.12B | |
-6.92% | 11.32B | |
-12.29% | 10.68B |
- Stock Market
- Equities
- KYTX Stock
- News Kyverna Therapeutics, Inc.
- Kyverna Therapeutics, Inc.'s KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients with Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial